

Aytu BioScience to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

ENGLEWOOD, Colo., Aug. 18, 2016 — Aytu BioScience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference, held September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.

Chief Executive Officer Josh Disbrow will provide an overview of the company's business during a live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Conference Details:

Event: Rodman & Renshaw 18th Annual Global Investment Conference

Date: Tuesday, September 13, 2016

Time: 10:00am - 10:25am (Eastern Time)

Location: Lotte New York Palace Hotel, New York

A live webcast of the presentation will be available online and archived on Aytu's Investors web page: <http://aytubio.com/investors/corporate-presentations-media/>.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets three products: Natesto[®], the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), ProstaScint[®] (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection, and Primsol[®] (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally, Aytu is developing MiOXSYS[™], a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information visit aytubio.com.

For Investors & Media:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664

Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

To view the original version on PR Newswire,

visit:<http://www.prnewswire.com/news-releases/aytu-bioscience-to-present-at-the-rodman-re-nshaw-18th-annual-global-investment-conference-300314776.html>

SOURCE Aytu BioScience, Inc.